CMML patient mutations in learning and validation cohorts
| Mutations . | Learning cohort (48 CMML)* . | Validation cohort (26 CMML)* . |
|---|---|---|
| TET2 (mutated/studied) | 36/48 | 14/26 |
| SRSF2 (mutated/studied) | 21/48 | 7/24 |
| ASXL1 (mutated/studied) | 13/48 | 5/26 |
| RAS Path (CBL+NRAS+KRAS) (mutated/studied) | 12/48 | 7/26 |
| AML1 (mutated/studied) | 6/48 | 3/26 |
| JAK2 (mutated/studied) | 1/48 | 1/26 |
| IDH1/IDH2 (mutated/studied) | 1/48 | 0/26 |
| ZRSR2 (mutated/studied) | 4/48 | 1/26 |
| DNMT3A (mutated/studied) | 3/48 | 2/25 |
| EZH2 (mutated/studied) | 1/48 | 2/25 |
| SF3B1 (mutated/studied) | 1/48 | 5/25 |
| FLT3 (mutated/studied) | 0/48 | 1/26 |
| NPM1, c-KIT, U2AF35 (mutated/studied) | 0/48 | 0/26 |
| Mutations . | Learning cohort (48 CMML)* . | Validation cohort (26 CMML)* . |
|---|---|---|
| TET2 (mutated/studied) | 36/48 | 14/26 |
| SRSF2 (mutated/studied) | 21/48 | 7/24 |
| ASXL1 (mutated/studied) | 13/48 | 5/26 |
| RAS Path (CBL+NRAS+KRAS) (mutated/studied) | 12/48 | 7/26 |
| AML1 (mutated/studied) | 6/48 | 3/26 |
| JAK2 (mutated/studied) | 1/48 | 1/26 |
| IDH1/IDH2 (mutated/studied) | 1/48 | 0/26 |
| ZRSR2 (mutated/studied) | 4/48 | 1/26 |
| DNMT3A (mutated/studied) | 3/48 | 2/25 |
| EZH2 (mutated/studied) | 1/48 | 2/25 |
| SF3B1 (mutated/studied) | 1/48 | 5/25 |
| FLT3 (mutated/studied) | 0/48 | 1/26 |
| NPM1, c-KIT, U2AF35 (mutated/studied) | 0/48 | 0/26 |
In these series, CMML patients were studied before any treatment.